Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & DohmefiledCriticalMerck Sharp & Dohme
Priority to CL2022002207ApriorityCriticalpatent/CL2022002207A1/en
Publication of CL2022002207A1publicationCriticalpatent/CL2022002207A1/en
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents
(AREA)
Abstract
La presente invención se refiere a formulaciones de vacuna contra el virus del dengue que comprenden al menos un virus del dengue vivo atenuado, un amortiguador, un azúcar, un derivado de celulosa, un glicol o alcohol de azúcar, opcionalmente un álcali o sal alcalina y un aminoácido.The present invention relates to dengue virus vaccine formulations comprising at least one live attenuated dengue virus, a buffer, a sugar, a cellulose derivative, a glycol or sugar alcohol, optionally an alkali or alkali salt, and an amino acid.
CL2022002207A2022-08-122022-08-12
Formulations of vaccine compositions against dengue virus (application divisional 202001463).
CL2022002207A1
(en)